TY - JOUR
T1 - Emerging treatments for primary sclerosing cholangitis
AU - Rodriguez, Eduardo A.
AU - Carey, Elizabeth J.
AU - Lindor, Keith D.
N1 - Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/5/4
Y1 - 2017/5/4
N2 - Introduction: Primary sclerosing cholangitis (PSC) is a chronic, cholestatic, idiopathic liver disease that can progress to end-stage liver disease, cirrhosis and cholangiocarcinoma. PSC is an uncommon and highly heterogeneous disease, associated with inflammatory bowel disease and a complex pathophysiology. To date, no medical therapies have proved effective. The only available treatment for end-stage PSC is liver transplant, but recurrence is a significant complication. Areas covered: This review will explore previously tested treatments, discuss current treatment strategies and present viewpoints about future emerging therapies in PSC. We searched PubMed using the noted keywords. We included data from full-text articles published in English. Further relevant articles were identified from the reference lists of review articles. Expert commentary: The development of new therapies in PSC has been challenging. However, with greater awareness of the disease nowadays, new insights into the disease may help in the design of future therapeutic agents in PSC and ultimately in effective therapies.
AB - Introduction: Primary sclerosing cholangitis (PSC) is a chronic, cholestatic, idiopathic liver disease that can progress to end-stage liver disease, cirrhosis and cholangiocarcinoma. PSC is an uncommon and highly heterogeneous disease, associated with inflammatory bowel disease and a complex pathophysiology. To date, no medical therapies have proved effective. The only available treatment for end-stage PSC is liver transplant, but recurrence is a significant complication. Areas covered: This review will explore previously tested treatments, discuss current treatment strategies and present viewpoints about future emerging therapies in PSC. We searched PubMed using the noted keywords. We included data from full-text articles published in English. Further relevant articles were identified from the reference lists of review articles. Expert commentary: The development of new therapies in PSC has been challenging. However, with greater awareness of the disease nowadays, new insights into the disease may help in the design of future therapeutic agents in PSC and ultimately in effective therapies.
KW - Primary sclerosing cholangitis
KW - antibiotics
KW - antifibrotic agents
KW - fecal microbiota transplantation
KW - obeticholic acid
KW - ursodeoxycholic acid
UR - http://www.scopus.com/inward/record.url?scp=85017548145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017548145&partnerID=8YFLogxK
U2 - 10.1080/17474124.2017.1293524
DO - 10.1080/17474124.2017.1293524
M3 - Review article
C2 - 28276816
AN - SCOPUS:85017548145
SN - 1747-4124
VL - 11
SP - 451
EP - 459
JO - Expert Review of Gastroenterology and Hepatology
JF - Expert Review of Gastroenterology and Hepatology
IS - 5
ER -